Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 271 to 280 of 281 total matches.
Cemiplimab (Libtayo) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
to biologic drugs to distinguish
reference products from their biosimilars.
meeting predetermined overall ...
The FDA has approved cemiplimab-rwlc (Libtayo –
Regeneron), an immune checkpoint inhibitor, for use in
combination with platinum-based chemotherapy for
first-line treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) in adults with no
epidermal growth factor receptor (EGFR), anaplastic
lymphoma kinase (ALK), or ROS1 aberrations and
who are not candidates for surgical resection or
chemoradiation. The drug was previously approved
for first-line treatment of NSCLC in patients whose
tumors have high PD-L1 expression and no genomic
tumor aberrations....
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e67-8 doi:10.58347/tml.2023.1674e | Show Introduction Hide Introduction
Dostarlimab (Jemperli) for Endometrial Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
duration of response was not
yet reached. The drug was also effective in patients
who had mismatch-repair ...
The FDA has granted regular approval to dostarlimabgxly
(Jemperli – GSK), an immune checkpoint
inhibitor, for treatment of adults with mismatch repair
deficient (dMMR) recurrent or advanced endometrial
cancer that has progressed on or following a prior
platinum-containing regimen in any setting and who
are not candidates for curative surgery or radiation.
Dostarlimab received accelerated approval in 2021
for treatment of adults with dMMR recurrent or
advanced endometrial cancer or nonendometrial
solid tumors that progressed on or following prior
treatment and who have no...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e64-5 doi:10.58347/tml.2023.1673h | Show Introduction Hide Introduction
Lotilaner (Xdemvy) for Demodex Blepharitis
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
orally, they can interact with many
other drugs. Tea tree oil and its derivatives are also
effective ...
The FDA has approved a 0.25% ophthalmic solution
of the ectoparasiticide lotilaner (Xdemvy – Tarsus) for
treatment of Demodex blepharitis. Lotilaner is the first
drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):99-100 doi:10.58347/tml.2024.1705b | Show Introduction Hide Introduction
Tislelizumab (Tevimbra) for Esophageal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
for second-line
treatment. All of these drugs can cause
significant toxicity.1,2
CLINICAL STUDIES ― FDA ...
The FDA has approved tislelizumab (Tevimbra –
BeiGene), a programmed death receptor-1 (PD-1)
blocking antibody, for treatment of unresectable
or metastatic esophageal squamous cell cancer in
adults who received prior systemic chemotherapy
that did not include a programmed death ligand-1
(PD-L1) inhibitor.
Med Lett Drugs Ther. 2024 May 13;66(1702):e85-6 doi:10.58347/tml.2024.1702h | Show Introduction Hide Introduction
Altuviiio – A Longer-Acting Factor VIII Product for Hemophilia A
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
replacement therapy.
FACTOR VIII PRODUCTS ― The interaction between
factor VIII and VWF imposes a ceiling ...
The FDA has approved Altuviiio (Sanofi), a von
Willebrand Factor (VWF)-independent, recombinant
factor VIII concentrate, for routine prophylaxis, on-demand
treatment to control bleeding episodes, and
perioperative management of bleeding in children and
adults with hemophilia A. The manufacturer claims that
Altuviiio, which was previously called efanesoctocog
alfa, delivers normal to near-normal factor VIII levels for
most of the week with once-weekly intravenous dosing.
Med Lett Drugs Ther. 2023 May 1;65(1675):67-8 doi:10.58347/tml.2023.1675b | Show Introduction Hide Introduction
Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
receptors, blocking its interaction
with PD-L1 and PD-L2 and restoring T cell antitumor
immune responses ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination with cisplatin and gemcitabine for
first-line treatment of recurrent locally advanced or
metastatic nasopharyngeal carcinoma and for use as
monotherapy for treatment of recurrent unresectable
or metastatic nasopharyngeal carcinoma in adults
with disease progression on or after platinum-based
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment of
nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7 doi:10.58347/tml.2024.1694e | Show Introduction Hide Introduction
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
is common and other allergic
reactions can occur.
DRUG INTERACTIONS — Coadministration of
antacids ...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62 doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction
A Fixed-Dose Combination of Finasteride and Tadalafil (Entadfi) for BPH (online only)
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
been reported with these drugs, but causality has not
been established.
DRUG AND LABORATORY INTERACTIONS — Use ...
The FDA has approved Entadfi (Veru), a fixed-dose
combination of the 5α-reductase inhibitor
finasteride and the phosphodiesterase type 5 (PDE5)
inhibitor tadalafil, for initial treatment of benign
prostatic hyperplasia (BPH) in men with an enlarged
prostate; use of the drug is limited to 26 weeks.
Entadfi is the first 5α-reductase inhibitor/PDE5
inhibitor combination to become available in the
US. Finasteride (Proscar, and generics) and tadalafil
(Cialis, and generics) are also available separately.
Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 10, 2022 (Issue 1641)
Table 1). They are the first
drugs to be authorized by the FDA for this indication.1
Two other pairs ...
The FDA has issued an Emergency Use Authorization
(EUA) for the investigational long-acting monoclonal
antibodies tixagevimab and cilgavimab (Evusheld –
AstraZeneca) to be administered concomitantly by IM
injection for pre-exposure prophylaxis of COVID-19 in
persons ≥12 years old who weigh ≥40 kg and have
either a history of severe allergy that prevents their
vaccination against COVID-19 or moderate or severe
immune compromise (see Table 1). They are the first
drugs to be authorized by the FDA for this indication.
Two other pairs of antibodies, bamlanivimab plus
etesevimab...
Pitolisant (Wakix) for Narcolepsy
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
in patients with narcolepsy.
Not a controlled substance, unlike other drugs approved for
these indications ...
The FDA has approved pitolisant (Wakix – Harmony), a histamine-3 (H3)-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is the first H3-receptor antagonist/inverse agonist to become available in the US and the first non-controlled substance to receive FDA approval for these indications. Pitolisant has been available in Europe since 2016.